Transgene Biotek Ltd
BSE:526139
Intrinsic Value
Transgene Biotek Ltd. is a biotechnology company, which manufactures and sells diagnostic kits. [ Read More ]
The intrinsic value of one TRABI stock under the Base Case scenario is hidden INR. Compared to the current market price of 6.36 INR, Transgene Biotek Ltd is hidden .
Valuation Backtest
Transgene Biotek Ltd
Run backtest to discover the historical profit from buying and selling TRABI stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Transgene Biotek Ltd
Current Assets | 9.6m |
Cash & Short-Term Investments | 105.1k |
Receivables | 84.5k |
Other Current Assets | 9.4m |
Non-Current Assets | 1.4B |
Long-Term Investments | 950.2k |
PP&E | 17.1m |
Intangibles | 65.6m |
Other Non-Current Assets | 1.3B |
Current Liabilities | 107.7m |
Accounts Payable | 2m |
Short-Term Debt | 85.5m |
Other Current Liabilities | 20.1m |
Non-Current Liabilities | 1.2B |
Long-Term Debt | 50.1m |
Other Non-Current Liabilities | 1.2B |
Earnings Waterfall
Transgene Biotek Ltd
Revenue
|
1.9m
INR
|
Cost of Revenue
|
-642.7k
INR
|
Gross Profit
|
1.3m
INR
|
Operating Expenses
|
-20.2m
INR
|
Operating Income
|
-19m
INR
|
Other Expenses
|
332.3k
INR
|
Net Income
|
-18.6m
INR
|
Free Cash Flow Analysis
Transgene Biotek Ltd
TRABI Profitability Score
Profitability Due Diligence
Transgene Biotek Ltd's profitability score is hidden . The higher the profitability score, the more profitable the company is.
Score
Transgene Biotek Ltd's profitability score is hidden . The higher the profitability score, the more profitable the company is.
TRABI Solvency Score
Solvency Due Diligence
Transgene Biotek Ltd's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Score
Transgene Biotek Ltd's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TRABI Price Targets Summary
Transgene Biotek Ltd
Shareholder Return
TRABI Price
Transgene Biotek Ltd
Average Annual Return | 4.48% |
Standard Deviation of Annual Returns | 70.23% |
Max Drawdown | -51% |
Market Capitalization | 481.9m INR |
Shares Outstanding | 75 770 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Transgene Biotek Ltd. is a biotechnology company, which manufactures and sells diagnostic kits. The company is headquartered in Medak, Telangana. The firm is engaged in a single business segment of Bulk Drugs. Its portfolio of products includes oncology, auto-immunity, drug delivery and biogenerics. The firm offers TrabiAAV, which is a platform for the delivery of micro ribonucleic acids (miRNAs), short hairpin RNA (ShRNAs), immunogens developing clinical significance in gene therapy. The company also offers monoclonal antibody therapy is the use of monoclonal antibodies to specifically bind to target cells. Its TrabiORAL focused on delivering proteins and peptides orally for a variety of human diseases. Its TBL-0404, is used for the treatment of metastatic liver cancer. Its TBL-1203, is used to strengthen cell-mediated immunity and complete elimination of the human immunodeficiency virus (HIV), without any need for retroviral drug therapy. Its Tacrolimus is a drug that suppresses the immune system and is mainly used to prevent rejection of transplanted organs.
Contact
IPO
Employees
Officers
The intrinsic value of one TRABI stock under the Base Case scenario is hidden INR.
Compared to the current market price of 6.36 INR, Transgene Biotek Ltd is hidden .